TARGET national: a UK-wide liquid-based molecular profiling programme: on behalf of the TARGET National Consortium
Name:
36335040.pdf
Size:
359.5Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UKIssue Date
2022
Metadata
Show full item recordCitation
Ortega-Franco A, Darlington E, Greystoke A, Krebs MG. TARGET National: A UK-wide Liquid-based Molecular Profiling Programme: On Behalf of the TARGET National Consortium. Clinical oncology (Royal College of Radiologists (Great Britain)). 2022 Nov 2. PubMed PMID: 36335040. Epub 2022/11/06. eng.Journal
Clinical OncologyDOI
10.1016/j.clon.2022.10.005PubMed ID
36335040Additional Links
https://dx.doi.org/10.1016/j.clon.2022.10.005Type
EditorialLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2022.10.005
Scopus Count
Collections
Related articles
- Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
- Authors: Madison R, Schrock AB, Castellanos E, Gregg JP, Snider J, Ali SM, Miller VA, Singal G, Alexander BM, Venstrom JM, Chung JH
- Issue date: 2020 Oct
- Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
- Authors: Francaviglia I, Magliacane G, Lazzari C, Grassini G, Brunetto E, Dal Cin E, Girlando S, Medicina D, Smart CE, Bulotta A, Gregorc V, Pecciarini L, Doglioni C, Cangi MG
- Issue date: 2019 Aug
- Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
- Authors: Pinto C, Biffoni M, Popoli P, Marchetti A, Marchetti P, Martini N, Normanno N
- Issue date: 2021 Sep
- Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
- Authors: Hicks JK, Saller J, Wang E, Boyle T, Gray JE
- Issue date: 2017 Sep
- High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
- Authors: Park S, Olsen S, Ku BM, Lee MS, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Ahn MJ
- Issue date: 2021 Aug 15